Time for life science companies to step forward and adopt GxP cloud computing
This article was originally published in SRA
Developing innovative products is the raison d’être of the world’s life science companies. Traditionally, however, such companies are hesitant when it comes to adopting innovative IT solutions – such as cloud computing – for their own businesses. With the introduction of NNIT’s GxP Cloud, that is about to change, European IT service provider NNIT tells Scrip Regulatory Affairs editor Maureen Kenny.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib